Search
Zitierungen und Referenzen (122)
Invitrogen™
Paclitaxel (Taxol Equivalent) - for use in research only
Invitrogen bietet Paclitaxel für Forschungszwecke nur mit einer Reinheit von >98 % durch HPLC an. Paclitaxel, früher in wissenschaftlicher LiteraturWeitere Informationen
| Katalognummer | Menge |
|---|---|
| P3456 | 5 mg |
Katalognummer P3456
Preis (EUR)
216,65
Exklusiv online
230,00Ersparnis 13,35 (6%)
Each
Menge:
5 mg
Preis (EUR)
216,65
Exklusiv online
230,00Ersparnis 13,35 (6%)
Each
Invitrogen bietet Paclitaxel für Forschungszwecke nur mit einer Reinheit von >98 % durch HPLC an. Paclitaxel, früher in wissenschaftlicher Literatur als Taxol bezeichnet, ist der zugelassene generische Name für das krebsbekämpfende pharmazeutische Taxol (ein eingetragenes Warenzeichen von Bristol-Myers Squibb Co). Paclitaxel fördert die Tubulin-Assemblierung und produziert Aggregate, die nicht durch Verdünnung, Calciumionen, Kälte oder eine Reihe von Mikrotubuli-zerstörenden Medikamenten depolymerisiert werden können. Kultivierte Zellen, die mit Paclitaxel behandelt werden, sind in den G2- und M-Phasen des Zellzyklus blockiert.
Nur für Forschungszwecke. Nicht zur Verwendung bei diagnostischen Verfahren.
Specifications
FormLyophilisiert
HemmstoffeCytoskelettinhibitor
Menge5 mg
VersandbedingungRaumtemperatur, Raumtemperatur
Spezifischer Inhibitor oder TargetTubulin
ProdukttypPaclitaxel
Unit SizeEach
Inhalt und Lagerung
Im Tiefkühlgerät lagern (-5 bis -30 °C).
Zitierungen und Referenzen (122)
Zitierungen und Referenzen
Abstract
A phase II study of taxol in patients with malignant melanoma.
Journal:Invest New Drugs
PubMed ID:1673965
Based on results of a phase I study demonstrating antitumor activity of taxol in patients with melanoma, 34 patients with documented metastatic melanoma received taxol, 250 mg/m2, as a 24-hours infusion, repeated every 21 days, in this phase II study. All patients received premedication with dexamethasone, diphenhydramine and cimetidine. Four
Regulation of melanosome movement in the cell cycle by reversible association with myosin V.
Journal:J Cell Biol
PubMed ID:10491390
'Previously, we have shown that melanosomes of Xenopus laevis melanophores are transported along both microtubules and actin filaments in a coordinated manner, and that myosin V is bound to purified melanosomes (Rogers, S., and V.I. Gelfand. 1998. Curr. Biol. 8:161-164). In the present study, we have demonstrated that myosin V
Chemical subdomains within the kinetochore domain of isolated CHO mitotic chromosomes.
Journal:J Cell Biol
PubMed ID:1830054
'We have used indirect immunofluorescence in combination with correlative EM to subdivide the mammalian kinetochore into two domains based on the localization of specific antigens. We demonstrate here that the fibrous corona on the distal face of the kinetochore plate contains tubulin (previously shown by Mitchison, T. J., and M.
Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria.
Journal:Cell
PubMed ID:9657148
'Mouse kif5B gene was disrupted by homologous recombination. kif5B-/- mice were embryonic lethal with a severe growth retardation at 9.5-11.5 days postcoitum. To analyze the significance of this conventional kinesin heavy chain in organelle transport, we studied the distribution of major organelles in the extraembryonic cells. The null mutant cells
Cdc42-interacting protein 4 mediates binding of the Wiskott-Aldrich syndrome protein to microtubules.
Journal:J Biol Chem
PubMed ID:10713100
'The Wiskott-Aldrich syndrome is an inherited X-linked immunodeficiency characterized by thrombocytopenia, eczema, and a tendency toward lymphoid malignancy. Lymphocytes from affected individuals have cytoskeletal abnormalities, and monocytes show impaired motility. The Wiskott-Aldrich syndrome protein (WASP) is a multi-domain protein involved in cytoskeletal organization. In a two-hybrid screen, we identified the